The short version of dual agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
== External links == Clinical trial number NCT06470828 for "A Study of TAK-861 for the Treatment of Narcolepsy Type 1" at ClinicalTrials.gov Clinical trial number NCT06505031 for "A Study of TAK-861 in People With Narcolepsy Type 1" at ClinicalTrials.gov
Calories consumed (food, drink) = Calories expended (basal metabolic rate, physical activity, thermogenic effect of food, acute illness) Outcome: Weight remains unchanged Calories consumed > Calories expended Also known as Positive Energy Balance Outcome: Weight increases Calories consumed < Calories expended Also known as Negative Energy Balance Outcome: Weight decreases The calories a person consumes come from food and drink intake. The calories a person expends comes from their basal metabolic rate and their daily physical activity. The human body is very good at maintaining a neutral energy balance, particularly with a diet composed of fruits, vegetables, and meats so that calories consumed do not substantially exceed calories expended in a given time period and vice versa. This energy balance is regulated by hormones like Leptin (suppresses), Ghrelin (stimulates), and Cholecystokinin (suppresses) which either suppress or stimulate appetite.
Protein purification is a series of processes intended to isolate one or a few proteins from a complex mixture, usually cells, tissues, or whole organisms. Protein purification is vital for the specification of the function, structure, and interactions of the protein of interest. The purification process may separate the protein and non-protein parts of the mixture, and finally separate the desired protein from all other proteins. Ideally, to study a protein of interest, it must be separated from other components of the cell so that contaminants will not interfere in the examination of the protein of interest's structure and function. Separation of one protein from all others is typically the most laborious aspect of protein purification. Separation steps usually exploit differences in protein size, physico-chemical properties, binding affinity, and biological activity. The pure result may be termed protein isolate.
== M == macroecology – macroevolution – macromolecules – major histocompatibility complex (MHC) – malaria – male – Malpighi layer – monophyletic – marburg virus – Marcello Malpighi – Marfan syndrome – marine biology – mass extinction – mathematical biology – mating – Max Delbrück – meiosis – membrane transporter – memory – memory cell – Mendelian inheritance – meristem – Mesowear – metabolism – metaphase – metapopulation – metazoa – Michaelis-Menten kinetics – microbe – microbiology – microevolution – microfilament – microsatellite – microscope – microtubules – Miller–Urey experiment – mimicry – Mitchell hypothesis – mitochondrial membrane – mitochondrion – mitosis – mitotic spindle – modern evolutionary synthesis – molecular biology – molecular clock – molecular evolution – molecular genetics – molecular phylogeny – mollusc – monoclonal antibody – morphogenesis – morphometrics – morula – MRI – MTT assay – mucous membrane - Muller's ratchet – multiresistance – muscle – mutagen – mutation – mutational meltdown – Mutualism (biology) – mycology – myosin
Charged aerosol detector electrically charged aerosol is used for the detection of non-UV-absorbing chargeable molecules, especially saccharides and lipids Evaporative light scattering detector evaporating non volatile solutes inside a volatile mobile phase for universal detection. used for saccharides and lipids and other non-UV-absorbing molecules In gas chromatography:
Sources: en.wikipedia.org
== Uses of plastinated specimens == Plastination is useful in anatomy, serving as models and teaching tools. It is used at more than 40 medical and dental schools throughout the world as an adjunct to anatomical dissection.
Newsom said: "Progressives and Democrats, nuns and priests, homeless advocates and homeless people were furious." The successfully passed ballot measure raised his political profile and provided the volunteers, donors, and campaign staff that helped make him a leading contender for mayor in 2003. In a 2008 city audit, the program was evaluated as largely successful for lowering average cash payments per person from over $300 to $78 and the number of people receiving cash payments from over 2,500 to about 640.
=== Promotion and release === Microsoft has been a major supporter for Compulsion Games in backing We Happy Few, leading to the game having its console debut on the Xbox One. Microsoft announced We Happy Few as part of their press conferences at Gamescom in August 2015, Electronic Entertainment Expo 2016. and Electronic Entertainment Expo 2018. This last presentation was accompanied by the news that Microsoft Studios had acquired Compulsion Games as part of their in-house studios. In August 2017, Compulsion Games announced that they have partnered with Gearbox Software for financial support to expand the game into a retail-length title, planned to release on 13 April 2018. Compulsion's Provost had known Gearbox's Randy Pitchford prior to their release of Contrast, and Contrast's visual style had caught Pitchford's attention, but the studio lacked a publishing arm at the time. By E3 2016, where Microsoft presented We Happy Few as part of its press event, Gearbox operated its Gearbox Publishing division led by Steve Gibson. Gibson, also interested in what We Happy Few offered, invited Compulsion to their offices to discuss financing and publishing opportunities for the game. Gearbox's funding helped Compulsion expand their team four-fold and expand the scope and narrative of the game. With Gearbox's help, Compulsion was able to develop We Happy Few for the PlayStation 4, while Gearbox will publish retail versions for all platforms; Microsoft's acquisition of the studio did not impact this publishing deal.
== Production and reactions == HMF was first reported in 1875 as an intermediate in the formation of levulinic acid from sugar and sulfuric acid. This remains the classical route, with 6-carbon sugars (hexoses) such as fructose undergoing acid catalyzed poly-dehydration. When hydrochloric acid is used 5-chloromethylfurfural is produced instead of HMF. Similar chemistry is seen with 5-carbon sugars (pentoses), which react with aqueous acid to form furfural.
antibody Any of a diverse family of glycoproteins known as immunoglobulins capable of binding specifically but reversibly via non-covalent interactions to a particular antigen or immunogen. Antibodies are generated as part of an organism's immune response to the introduction of a specific antigen into a host organism, and their binding of the antigen frequently (though not always) counteracts or inhibits any biological activity the antigen may have. Antibodies have a characteristic Y-shaped structure consisting of a heavy chain and light chain held together by disulfide bonds.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
它属于合成修饰肽，同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂，与选择性 GLP-1 激动剂在靶点范围上不同。